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ASXL2 is essential for haematopoiesis and acts
as a haploinsufﬁcient tumour suppressor in
leukemia
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Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex
combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has
been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its
paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the
RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal
haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a
haploinsufﬁcient tumour suppressor. While Asxl2 was required for normal haematopoietic
stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2
target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was
associated with increased chromatin accessibility at putative enhancers of key leukemogenic
loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates
transcriptional effects that promote leukemogenesis driven by AML1-ETO.
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R
egulation of gene expression through the function of
polycomb and trithorax protein complexes is critical for
normal haematopoiesis1–5. The discovery of frequent
mutations in the polycomb-associated protein additional sex
combs-like, ASXL1 (refs 6–8), resulted in efforts to understand its
role in haematopoiesis. However, ASXL1 is one of three
mammalian paralogues of Asx, a protein required for both
activation and silencing of Hox genes in Drosophila. Asxl2, in
particular, shares a common expression pattern in embryogenesis
and haematopoiesis with Asxl1 (refs 9–11), while Asxl3, in
contrast, is not expressed in haematopoietic cells12. Moreover,
ASXL1 and ASXL2 are encoded from paralogous regions of the
genome at the DNMT3B-ASXL1-KIF3B (20q11.21) and
DNMT3A-ASXL2-KIF3C (2p23.3) loci, respectively. Given these
features and the fact that ASXL1 and ASXL2 also share common
domains, it has been suggested that ASXL1 and ASXL2 may have
overlapping, partially redundant, or even opposing functions13.
ASXL2 has recently been identiﬁed as among the most
commonly mutated genes in AML patients bearing the
AML1-ETO fusion oncoprotein14–16 (encoded by translocation
t(8;21)). At the same time, unlike mutations in ASXL1, ASXL2
mutations are virtually absent in other forms of leukemia or in
clonal haematopoiesis17–19, suggesting a speciﬁc genetic
interaction between ASXL2 and AML1-ETO. Given that
expression of the AML1-ETO fusion is not sufﬁcient to
generate overt AML on its own20–24, the unique enrichment of
ASXL2 mutations in this subset of AML suggests that ASXL2
mutations may be an important cooperating genetic alteration in
the pathogenesis of AML1-ETO AML. Currently however, very
little is known about the role of ASXL2 in normal or malignant
haematopoiesis. Here we set out to deﬁne the role of ASXL2 in
normal and malignant haematopoiesis, to compare its effects on
gene expression and chromatin state to those of ASXL1, and to
understand the functional basis for ASXL2 mutations in the
context of AML1-ETO-mediated AML. We identify that Asxl2 is
required for normal haematopoietic stem cell self-renewal
and has non-redundant roles with Asxl1. Moreover, loss
of Asxl2 altered chromatin state at key leukemogenic loci in
AML1-ETO-expressing cells and loss of even a single copy of
Asxl2 promotes AML1-ETO leukemogenesis.
Results
ASXL2 mutations result in loss of ASXL2 protein expression.
Four recent studies have identiﬁed that ASXL2 mutations are
present in 19.8–22.7% of pediatric and adult patients with t(8;21)
AML14–16,25. Across these studies, mutations in ASXL2 occured
as out-of-frame insertion/deletion mutations and nonsense muta-
tions in exons 11–12 of ASXL2. To evaluate the effects of ASXL2
mutations on ASXL2 expression, we generated mammalian
expression vectors encoding full-length wild-type (WT) ASXL2
(1–1435) and two ASXL2 mutations documented in AML15
(ASXL2 p.T740NfsX16 and p.E1287X). Expression of WT ASXL2
cDNA or cDNA constructs bearing leukemia-associated mutant
forms of ASXL2 revealed reduced stability of mutant ASXL2
relative to WT ASXL2, with greater loss of mutant ASXL2
following cycloheximide exposure (Supplementary Fig. 1a,b).
These data suggest that mutations in ASXL2 are most likely
loss-of-function mutations.
Generation of Asxl2 conditional knockout mice. Prior efforts to
study the effects of ASXL2 loss in vivo have been limited by
the fact that constitutive deletion of Asxl2 is associated with
substantial perinatal lethality10 and, to date, no models allowing
complete post-natal or conditional, tissue-speciﬁc deletion of
Asxl2 have been established. Given the above data, and the fact
that human ASXL2 shares 79.4% total amino acid homology
with mouse Asxl2, we generated a conditional allele targeting
Asxl2 (Fig. 1a and Supplementary Fig. 1c). Embryonic
stem cell targeting was used to insert two LoxP sites ﬂanking
exon 11 of Asxl2, as well as a Frt-ﬂanked neomycin
selection cassette in the upstream intron. The generated mice
(Asxl2ﬂ/ﬂ) were initially crossed to a germline Flp-deleter mouse
line to remove the neomycin cassette and then subsequently
crossed to IFN-a-inducible Mx1-cre transgenic mice to allow
for inducible deletion of Asxl2 in post-natal tissues. Western
blotting (WB) and quantitative PCR with reverse transcription
of bone marrow (BM) mononuclear cells (MNCs) from
Mx1-cre Asxl2ﬂ/ﬂ mice 4 weeks after administration
of polyinosinic:polycytidylic acid (pIpC) revealed that Asxl2
protein expression was fully eliminated in this model and
that Asxl2 deletion was not associated with altered Asxl1
expression at the protein or mRNA level (Fig. 1b,c and Suppleme-
ntary Table 1).
Asxl2 is required for normal haematopoiesis. We next sought to
delineate the role of Asxl2 on haematopoiesis and its potential
redundancy with Asxl1. We and others have previously noted
that Asxl1 loss in post-natal haematopoiesis is associated with
modest leukopenia, anaemia and a myelodysplastic syndrome-
like phenotype in mice after a long latency26,27. We therefore
generated CD45.2 Mx1-cre control, Mx1-cre Asxl2ﬂ/ﬂ, Mx1-cre
Asxl1ﬂ/ﬂ and compound Mx1-cre Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ mice.
To study the cell-autonomous effect of Asxl1/2 deletion in
a haematopoieitic-speciﬁc manner, we performed noncompetitive
BM transplantation (BMT) using these mice (n¼ 3–5 donors per
genotype) into 10 lethally irradiated CD45.1 recipient mice per
donor (Fig. 1d). This was then followed by peripheral blood
analysis of the recipient mice and pIpC administration to delete
Asxl2 and/or Asxl1 in the haematopoietic system.
Analysis of peripheral blood of Asxl2-deﬁcient mice revealed
that in contrast to the modest effects of Asxl1 deletion on white
blood cell (WBC) and platelet counts, Asxl2 deletion resulted in
rapid leukopenia and thrombocytopenia in recipient mice which
was associated with hastened death of recipient mice (Fig. 1e–g).
Moreover, mice with compound deletion of Asxl1 and Asxl2 had
even lower WBC and platelet counts than single knockout
controls. The decrease in peripheral blood MNCs in mice with
Asxl2 and compound Asxl1/2 deletion was mostly attributed to
decrements in B220þ mature B-cells and CD3þ T-cells
(Supplementary Fig. 1d,e). Moreover, the lower peripheral blood
platelet numbers in Asxl2-deﬁcient mice was associated with
signiﬁcant decrease in the number of BM megakaryocytes as well
as reduced colony formation of megakaryocyte progenitors
puriﬁed from haematopoietic stem and progenitor cells (HSPCs)
from Asxl2-deﬁcient mice relative to Asxl1-deﬁcient or control
Asxl1/2-WT mice (Supplementary Fig. 1f–g).
Morphological analysis of BM histology sections revealed
abnormal BM clustering of megakaryocytes that is consistent with
defective megakaryocyte differentiation in Asxl2-deﬁcient mice
(Supplementary Fig. 2). Moreover, Asxl2-deﬁcient mice exhibited
hyposegmented neutrophils with hypogranular cytoplasm and
circulating, multinucleated erythroid progenitors, which are features
consistent with myelodysplasia (Supplementary Fig. 2b,c). Asxl1-
deﬁcient BM showed morphologic evidence of dysplasia in myeloid
cells and megakaryocytes as previously reported26,27, a feature
that was also evident in mice with compound Asxl1/2 deletion
(Supplementary Fig. 2a). Of note, longitudinal evaluation of
recipient mice transplanted with Mx1-cre Asxl2ﬂ/ﬂ mice up to 52
weeks failed to reveal any Asxl2-deﬁcient mice to have developed
increased white blood counts, splenomegaly or expansion of HSPCs
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(Supplementary Fig. 3). This ﬁnding suggests that Asxl2-deﬁcient
haematopoietic cells result in functional defects in haematopoiesis
that are associated with shortened survival in the mice. Overall, these
data reveal that Asxl2 is required for normal haematopoiesis and has
distinct and non-redundant effects compared with Asxl1 in
haematopoiesis.
Asxl2 is required for haematopoietic stem cell self-renewal. We
next assessed the effect of Asxl2 or compound Asxl1/2 loss
on HSPC frequency and function. We ﬁrst performed
serial competitive BMT assays using 500,000 BM MNCs from
6-week-old CD45.2 Mx1-cre control, Mx1-cre Asxl2ﬂ/ﬂ, Mx1-cre
Asxl1ﬂ/ﬂ and compound Mx1-cre Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ mice
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Figure 1 | Asxl2 is required for normal haematopoiesis. (a) Asxl2 conditional knockout allele. (b) Western Blot of bone marrow (BM) cells from Mx1-cre
control and Mx1-cre Asxl2ﬂ/ﬂ primary mice 4 weeks post-polyinosinic:polycytidylic acid (pIpC) adminstration. (c) Expression of Asxl1, Asxl2, and Asxl3 by
qRT-PCR in BM mononuclear cells from Mx1-cre Asxl2ﬂ/ﬂ primary mice 4 weeks post-pIpC relative to each gene from Mx1-cre controls. (d) Schema for
noncompetitive BM transplantation using CD45.2+ Mx1-cre control (black), Mx1-cre Asxl2ﬂ/ﬂ (red), Mx1-cre Asxl2ﬂ/ﬂ (blue), and Mx1-cre Asxl2ﬂ/ﬂ
Asxl2ﬂ/ﬂ (purple) mice. (e–f) Enumeration of white blood cells (WBC) (e) and platelets (f) in peripheral blood of CD45.1 recipient mice following
noncompetitive BM transplantation from CD45.2+ mice as shown in (d) (n = 10 mice/genotype; pIpC was administered to recipient mice 4 weeks
following transplantation). (g) Kaplan-Meier survival curve of recipient mice transplanted with Mx1-cre control and Mx1-cre Asxl2ﬂ/ﬂ BM cells
(n=10 mice/genotype). Error bars represent mean±s.d. *Po0.05, **Po0.001, ****Po0.0001; P-values calculated by ordinary one-way ANOVA test.
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pre-pIpC injection. These were injected with equal numbers of
CD45.1 BM MNCs into lethally irradiated CD45.1 recipients
(10 recipients per genotype) (Fig. 2a). Recipient mice were then
bled 4 weeks later to establish baseline chimerism followed by
pIpC injection and monthly bleeding for 16 weeks post pIpC,
following which mice were killed and serial transplantation
was performed. Consistent with the effect of Asxl2 deletion on
haematopoiesis in noncompetitive transplantation, Asxl2 loss was
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associated with rapid loss of haematopoiesis at both the level of
mature circulating blood leukocytes and BM HSPCs (Fig. 2b,c).
The effects of Asxl1 loss on HSPCs, in contrast, were evident only
on serial transplantation. At 16-weeks post transplantation, Asxl2
loss was associated with loss of long-term haematopoietic stem
cells (lineage-negative Sca 1þ c-Kitþ CD150þ CD48 cells)
as well as more intermediate haematopoietic progenitor cell
populations (haematopoietic progenitor fraction 1 and 2
(HPC 1 and HPC 2)28), phenotypes not seen with Asxl1 loss
(Fig. 2d and Supplementary Fig. 4a).
Given that ASXL2 mutations occur as heterozygous mutations
in leukemia patients14,15, we also investigated the effects
of heterozygous loss of Asxl2. Competitive transplantation of
Mx1-cre Asxl2ﬂ/WT mice versus Mx1-cre Asxl2ﬂ/ﬂ and Mx1-cre
control mice revealed that deletion of even a single copy of Asxl2
was associated with substantial decrements in HSPC self-renewal
(Fig. 2e,f). These data reveal that Asxl2 is haploinsufﬁcient with
regards to normal HSPC function.
Of note, the effects of Asxl2 loss in the noncompetitive
transplantation setting were also seen in the setting of primary,
non-transplanted Mx1-cre Asxl2ﬂ/ﬂ mice relative to controls
(Supplementary Fig. 4b–f). A cohort of 6 primary Mx1-cre
Asxl2 WT, Mx1-cre Asxl2ﬂ/WT and Mx1-cre Asxl2ﬂ/ﬂ mice were
treated with pIpC at 6 weeks of age and then followed for
26 weeks post pIpC. Mx1-cre Asxl2ﬂ/WT, and Mx1-cre Asxl2ﬂ/ﬂ
mice consistently exhibited lower periperhal blood WBCs
(primarily due to lower B220þ cells in the peripheral blood)
as well as platelet counts compared toMx1-cre Asxl2WT controls
(Supplementary Fig. 4b,c). Consistent with results in transplanta-
tion setting, signiﬁcant reductions in absolute numbers
of multipotent progenitors (MPPs), LSK cells and megakaryo-
cyte/erythroid progenitor (MEP) cells as well as percentage
of splenic erythroid precursors (CD71þ Ter119 cells) and
megakaryocytes (CD41þ cells) were seen in Mx1-cre Asxl2ﬂ/ﬂ
mice compared with Mx1-cre control mice (Supplementary
Fig. 4d–f). Mx1-cre Asxl2ﬂ/wt mice also exhibited signiﬁcant
reductions in absolute numbers of MEPs as well as splenic
erythroid precursors (CD71þ Ter119 cells) and megakaryo-
cytes (CD41þ cells) compared with Mx1-cre control mice
(Supplementary Fig. 4d–f). These data further afﬁrm that Asxl2
is required for normal haematopoiesis.
Asxl2 target genes overlap with those of RUNX1 and AML1-ETO.
We next sought to understand the mechanistic effects of Asxl2
loss on haematopoiesis by analysing the transcriptional and
epigenomic effects of Asxl2 loss. We performed mRNA sequen-
cing (RNA-seq) of puriﬁed BM CD45.2þ lineage-negative
Sca 1þ c-Kitþ (LSK) cells from Mx1-cre Asxl2ﬂ/ﬂ, Mx1-cre
Asxl1ﬂ/ﬂ, and Mx1-cre control mice 4-weeks following
pIpC administration. In contrast to the 129 genes signiﬁcantly
(multiple hypothesis adjusted Po0.05) differentially expressed in
Asxl1-deﬁcient LSK cells relative to controls, 2,986 genes were
dysregulated in Asxl2-deﬁcient LSK cells relative to controls
(Fig. 3a and Supplementary Data 1). Moreover, only a small
number of dysregulated genes were shared amongst Asxl1- versus
Asxl2-null LSK cells (Fig. 3b). Interestingly, genes differentially
expressed following Asxl2 loss signiﬁcantly overlapped with
genes previously described as upregulated by the AML1-ETO
oncoprotein29, a ﬁnding not seen amongst differentially expressed
genes from Asxl1-deﬁcient LSK cells (Fig. 3c). AML1-ETO is
a transcriptional regulator whose genome-wide direct binding
targets have been extensively mapped in human t(8;21) AML
cell lines30–33 and are known to overlap with binding targets of
wild-type RUNX1 (refs 33,34). We therefore next examined the
overlap between genes differentially expressed in Asxl2-deﬁcient
LSK cells and those which are known targets of AML1-ETO or
RUNX1 based on previously published chromatin immuno-
precipitation next-generation sequencing (ChIP-seq) studies in
ASXL1/2-WT AML1-ETO-expressing human AML cells29,30.
These data again revealed substantial overlap of direct
AML1-ETO and RUNX1 gene targets amongst genes altered by
Asxl2 deletion, but not by Asxl1 deletion (Fig. 3c).
Overlap of ASXL2 and AML1-ETO target genes in AML cells.
The above data suggested an overlap of Asxl2-binding sites and
transcriptional targets of AML1-ETO in the setting of normal
haematopoiesis and without introduction of the AML1-ETO
oncofusion protein. We therefore next sought to examine the
transcriptional and epigenetic effects of ASXL2 loss in the setting of
human AML expressing endogenous AML1-ETO. Comparison of
ASXL2 genome-wide binding to RUNX1 and AML1-ETO-binding
sites in SKNO 1 cells (a human AML1-ETO cell line WT for
ASXL1 and ASXL2 (in contrast to the commonly studied Kasumi
series of AML1-ETO-expressing cell lines which bear endogenous
ASXL1 mutation35)) revealed that ASXL2 displayed less
enrichment at transcriptional start sites (TSS) than RUNX1 or
AML1-ETO (Fig. 3d). Given the likely different enrichment
efﬁciencies between antibodies used in ChIP-seq here and the
different number of peaks across the different immunoprecipitated
proteins, we also evaluated the percentage of ASXL2, AML1-ETO
and RUNX1 peaks that overlap with promoters (deﬁned as 2.5 to
þ 2.5 kb of TSS). The percentage of promoter-overlapping peaks
for ASXL2, AML1-ETO and RUNX1 were 9.7, 27 and 29.8%
respectively. Although these data suggest that ASXL2 binds fewer
TSS than AML1-ETO and RUNX1, ASXL2 binding was strongly
enriched at AML1-ETO-binding sites (Fig. 3d–f, Supplementary
Fig. 5 and Supplementary Data 2–4). Thus, in the setting of both
normal and malignant haematopoietic cells, direct binding sites of
ASXL2 strongly overlapped with those of AML1-ETO and RUNX1
(ChIP-seq enrichment for AML1-ETO, RUNX1 and ASXL2 at
representative loci are shown in Supplementary Fig. 5a). Consistent
with this, motif enrichment analysis of ASXL2-binding sites in
these same SKNO 1 cells revealed a strong overlap of ASXL2
binding with ETS as well as AP 1 transcription factors, all
established as interacting physically with the AML1-ETO
transcriptional complex in human t(8;21) (ref. 33) AML
Figure 2 | Asxl2 is required for haematopoietic stem cell self-renewal. (a) Schema of serial competitive BMT assays from CD45.2þ Mx1-cre control
(black),Mx1-cre Asxl1ﬂ/ﬂ (red),Mx1-cre Asxl2ﬂ/ﬂ (blue) andMx1-cre Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ (purple) mice. (b) Percentage of CD45.2þ chimerism in the peripheral
blood of recipient mice over time (n¼ 10 mice/genotype) in primary (1 o), secondary (2 o) and tertiary (3 o) BMT. (c) Flow cytometric enumeration of
CD45.2þ lineage-negative Sca1þ cKitþ (LSK) cells in the BM ofMx1-cre control,Mx1-cre Asxl1ﬂ/ﬂ, Mx1-cre Asxl2ﬂ/ﬂ andMx1-cre Asxl1ﬂ/ﬂ & Asxl2ﬂ/ﬂmice
14 weeks after polyinosinic:polycytidylic acid (pIpC) injection in competitive transplant. (d) Total number of BM MP, LSK cells, LT-HSC, restricted
haematopoietic progenitor cell fractions 1 (HPC-1) and 2 (HPC-2) and MPP cells following noncompetitive BMT from the indicated genotypes (as shown in
Fig. 1d; n¼ 5 mice/genotype). (e) Percentage of CD45.2þ chimerism in the peripheral blood of recipient mice transplanted with CD45.2Mx-1 control,Mx1-cre
Asxl2ﬂ/WT, or Mx1-cre Asxl2ﬂ/ﬂ BM cells over time (n¼ 10 mice/genotype). (f) Flow cytometric enumeration of CD45.2þ LSK cells in the BM of mice from
e 14 weeks after pIpC injection in competitive transplant. Error bars represent mean±s.d.; *Po0.05, **Po0.001, ***Po0.0002, ****Po0.0001. P values
calculated by ordinary one-way ANOVA test. ANOVA, analysis of variance; LT-HSC, long-term haematopoietic stem cells.
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(Supplementary Fig. 5d; Supplementary Data 5 shows all
signiﬁcantly enriched motifs under ASXL2 ChIP-seq peaks, of
which ETS and AP 1 motifs represent only a subset).
Given the overlap of ASXL2, RUNX1 and AML1-ETO-binding
sites we also sought to examine if there was a direct physical
interaction of these proteins. However, co-immunoprecipitation
experiments failed to reveal physical interaction of RUNX1,
AML1-ETO or AML1-ETO9a with ASXL2 (Supplementary
Fig. 6a,b).
H3K27me3 loss and alterations at enhancers with ASXL2 loss.
In addition to potential direct transcriptional effects, prior work
from us36 and others27,37 has identiﬁed that ASXL1 alterations
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Figure 3 | ASXL2 target genes overlap with those of RUNX1 and AML1-ETO. (a) Heatmap of signiﬁcantly differentially expressed genes in LSK cells from
Mx1-cre Asx1ﬂ/ﬂ or Mx1-cre Asxl2ﬂ/ﬂ mice relative to Mx1-control mice (genes shown are those restricted to differential expression with multiple hypothesis
adjusted P value of Po0.05). (b) Venn diagram of differentially expressed genes in Mx1-cre Asxl1ﬂ/ﬂ and Mx1-cre Asxl2ﬂ/ﬂ LSK cells relative to control
(genes restricted to P value cutoff described for a). (c) GSEA of genes enriched in Mx1-cre Asxl2ﬂ/ﬂ LSK cells (right), with plots of enrichment for same gene
sets in Mx1-cre Asxl1ﬂ/ﬂ shown on left for comparison. (d) The average binding intensity of RUNX1, AML1-ETO and ASXL2 centred on TSSs±1 kB in SKNO-1
cells. (e) The average binding intensity of ASXL2 centred on AML1-ETO-binding sites±1 kB in SKNO-1 cells. (f) Overlap of RUNX1, AML1-ETO and ASXL2
binding sites in SKNO1-cells. ChIP-seq reads in d–f were normalized as read counts per million mapped reads. GSEA, gene set enrichment analysis.
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Figure 4 | Effects of ASXL2 loss on chromatin state of AML1-ETO leukemic cells. (a) Anti-H3K27me3 ChIP-seq signal intensity centred at TSSs±3 kB or
(b) gene-bodies±5 kB in SKNO-1 cells treated with control shRNA and two different anti-ASXL1 and ASXL2 shRNAs. TES; transcription end site. (c) Mean
anti-H3K4me1 ChIP-seq signal density at putative active (top) and poised enhancers (bottom; deﬁned as enhancers marked by H3K4me1 and H3K27Ac
signal or just H3K4me1 signal, respectively) in SKNO-1 cells with or without ASXL2 downregulation. ChIP-seq reads in a–c were normalized and displayed
as read counts per million mapped reads. (d,e) Data from c displayed as a heatmap representation of H3K4me1 ChIP-seq signal at putative (d) active and
(e) poised enhancers in SKNO-1 cells with control shRNA or one of two different ASXL2 shRNAs. (f) anti-H3K27me3, H3K4me1 and H3K27Ac ChIP-seq
proﬁles (displayed as read counts per million mapped reads) at the HOXA locus in SKNO-1 cells with control shRNA or anti-ASXL1 or ASXL2 shRNAs.
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are associated with global downregulation of histone H3 lysine 27
trimethylation (H3K27me3). Interestingly, while ASXL1 loss in
SKNO-1 cells was associated with clear downregulation of
H3K27me3 at TSS and gene bodies, ASXL2-deﬁcient cells had
less prominent H3K27me3 loss in comparison (Fig. 4a,b,
Supplementary Fig. 6c–e and Supplementary Table 1). Similarly,
Asxl1-deﬁcient haematopoietic progenitors exhibited global
downregulation of H3K27me3 which was not seen in Asxl2-
deﬁcient progenitors based on both western blotting as well as
anti-H3K27me3
ChIP-seq (Supplementary Fig. 6f,g). Finally, given prior reports
for roles of ASXL1 as well as ASXL2 in PRC2-mediated
H3K27me3, we evaluated for a potential physical interaction
between ASXL2 or ASXL1 and PRC2 components. Despite
evidence of clear physical interaction between ASXL1, ASXL2,
and BAP1 (as previously reported38) as well as ASXL1 and the
core PRC2 member SUZ12 (also previously reported36),
interaction between ASXL2 and PRC2 members were not
evident (Supplementary Fig. 6b).
We therefore next examined the effects of ASXL2 loss on the
state of other histone post-translational modiﬁcations known to be
regulated by Polycomb and/or Trithorax group protein complexes.
While ASXL2 loss had no clear effect on histone H3 lysine 4
trimethylation (H3K4me3) at TSS (Supplementary Fig. 6h), ASXL2
loss was associated with increases in H3K27ac and H3K4me1 signal
at putative active enhancers (marked by both H3K27ac and
H3K4me1) as well as poised enhancers (marked by H3K4me1
without H3K27ac) as seen by anti-H3K4me1 and anti-H3K27Ac
ChIP-seq following ASXL2 depletion using two independent
shRNAs targeting ASXL2 (Fig. 4c–f). To correlate alterations in
histone modiﬁcations following ASXL2 loss in AML1-ETO
leukemic with genes differentially expressed by ASXL2 loss we
performed RNA-seq analysis of SKNO1 cells treated with control
shRNA or 2 different anti-ASXL2 shRNAs, each in biological
triplicate (Supplementary Fig. 7a and Supplementary Data 6–7).
Interestingly, this identiﬁed a number of genes known to promote
leukemogenesis (either alone or in the context of AML1-ETO
leukemia) as differentially expressed by ASXL2 loss. These include
downregulation of TET2 as well as NOTCH2 with ASXL2 loss in
human AML1-ETO-expressing cells, downregulation of which have
been previously shown to functionally promote myeloid leukemo-
genesis when altered in expression24,39,40. Next, we utilized these
RNA-seq data to evaluate the overlap of differentially expressed
genes with direct targets of ASXL2, RUNX1, and AML1-ETO as
well as alterations in H3K27me3, H3K4me1 and H3K27Ac. This
revealed that B90% of genes dysregulated in expression with
ASXL2 loss are direct targets of RUNX1 or RUNX1-ETO
(Supplementary Fig. 7b). There was no clear correlation between
the loss of H3K27me3 upon ASXL2 knockdown and alterations in
gene expression (Supplementary Fig. 7c). Similarly, genes within
100 kB of H3K4me1 or H3K27Ac peaks in shControl cells did not
experience consistent alterations in gene expression following
ASXL2 loss (although this may be explained by the fact that these
are putative enhancers that do not necessarily regulate the
expression of genes located in 100 kB proximity of these genes;
Supplementary Fig. 7d,e).
To evaluate if the histone modiﬁcations seen with ASXL2 loss
were alterated at ASXL2 or AML1-ETO-binding sites speciﬁcally,
we analysed the H3K27me3 and H3K4me1 abundance at ASXL2
peaks as well as AML1-ETO peaks in SKNO-1 cells treated with
control shRNA or one of 2 different anti-ASXL2 shRNAs.
Although changes in H3K27me3 were more prominent at
ASXL2 or AML1-ETO peaks than at random control regions
of the genome outside of these peaks (Supplementary Fig. 7f,g),
H3K27me3 changes were prominent across TSS and gene bodies
(Fig. 4a,b). Moreover, there was no clear correlation between
changes in H3K4me1 and sites of ASXL2 binding (Supplementary
Fig. 7h) suggesting that alterations in H3K27me3 and H3K4me1
did not have a speciﬁc relation to ASXL2-binding sites.
Asxl2 loss promotes AML1-ETO-mediated leukemogenesis.
Genetic analyses of patients with t(8;21) AML and extensive
animal modelling of the haematopoietic effects of the AML1-ETO
translocation have identiﬁed that AML1-ETO is expressed in
early HSCs and increases self-renewal but is not sufﬁcient for
leukemogenesis alone20–22. Substantial effort has therefore been
spent to identify genetic events that collaborate with AML1-ETO
to promote leukemogenesis. Recent genomic analyses of
AML1-ETO AML patients have identiﬁed that the average
variant allele frequency of mutations in ASXL2 are signiﬁcantly
higher than those of other mutations frequently co-existing with
AML1-ETO such as c-KIT, FLT3 and N/KRAS mutations25.
Consistent with this, unsupervised hierarchical clustering of
differentially expressed genes amongst AML patients with
the AML1-ETO translocation revealed that ASXL2-mutant
AML1-ETO samples form a distinct transcriptional subset of
AML1-ETO AML, an effect not seen with other common genetic
alterations in AML1-ETO AML (Fig. 5a).
Given the above human genetic data we next sought to
examine the contribution of ASXL2 loss to AML1-ETO-mediated
leukemia. We performed murine retroviral BMT assays over-
expressing full-length AML1-ETO or the AML1-ETO9A (AE9a)
splice isoform41 linked to GFP in BM cells from Asxl2-deﬁcient
or control mice followed by transplantation into WT C57BL/6
recipients (Supplementary Fig. 8a,b). Converse to the failure of
HSC self-renewal with deletion of Asxl2 in normal haemato-
poiesis, loss of Asxl2 in the setting of either full-length
AML1-ETO or AE9a overexpression consistently led to
hastened death due to shortened latency of leukemogenicity
compared with AML1-ETO or AE9a overexpression in an Asxl2
WT background (Fig. 5b,c). Consistent with this, mice
transplanted with AE9a/Asxl2-null leukemias had a higher
frequency of GFP/c-Kit double-positive cells in both peripheral
blood and BM at the time of death (Supplementary Fig. 8c).
Next to study leukemogenesis mediated by AML1-ETO and
ASXL2 loss in the genetic conﬁguration most representative of
human AML, we crossed mice bearing expression of the Aml1-Eto
fusion from the endogenous locus of Aml1 (Aml1-Eto conditional
knockin mice23) to Mx1-cre Asxl2ﬂ/ﬂ mice to generate Mx1-cre
Aml1-Eto Asxl2ﬂ/WT and Mx1-cre Aml1-Eto Asxl2 WT mice
(Supplementary Fig. 9a–c). Heterozygous loss of Asxl2 collaborated
with expression of endogenous Aml1-Eto to promote leukemo-
genesis (Fig. 5d). Moreover, Mx1-cre Aml1-Eto Asxl2ﬂ/WT mice
developed prominent extramedullary leukemic inﬁltration in soft
tissues, a clinical characteristic often seen in patients with this
subtype of AML42,43 (Fig. 5e–g and Supplementary Fig. 9d). Finally,
to model the effects of coexistent oncogenic RAS mutations,
which are present in a subset of AML1-ETO/ASXL2-mutant
AML patients25, expression of NRASG12D in Mx1-cre Aml1-Eto
Asxl2ﬂ/WT and Mx1-cre Aml1-Eto Asxl2 WT BM backgrounds
resulted in further collaborative effects in the AML1-ETO/ASXL2
haploinsufﬁcient background (Fig. 5d and Supplementary
Fig. 9e–h). Mx1-cre Aml1-Eto Asxl2ﬂ/WT mice expressing
NRASG12D developed worsened anaemia and thrombocytopenia
as well as greater circulating GFP/c-Kit double-positive cells and
hastened death compared with counterpart Mx1-cre Aml1-Eto
Asxl2 WT mice expressing NRASG12D.
Given the alterations of enhancers in human AML1-ETO
cells with ASXL2 loss, we next examined the chromatin state
of AE9a leukemias with or without Asxl2 expression by
transposase-accessible chromatin sequencing (ATAC-Seq).
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Although global chromatin accessibility as assessed by ATAC-seq
of GFP/c-Kit double-positive cells from two independent
AE9a/Mx1-cre control and 2 AE9a/Mx1-cre Asxl2ﬂ/ﬂ mice
did not reveal substantial global differences between groups
(Supplementary Fig. 10), there was a striking increase
in chromatin accessibility at the HoxA and Meis1 loci of
AE9a/Mx1-cre Asxl2ﬂ/ﬂ mice compared to AE9a control mice
with Asxl2 intact (Fig. 5h). These data suggest that Asxl2 loss
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Figure 5 | Asxl2 loss promotes AML1-ETO-mediated leukemogenesis. (a) Heatmap displaying unsupervised hierarchical clustering of differentially
expressed genes amongst AML1-ETO patient BM samples at diagnosis. Genes mutated in each sample is shown above the heatmap. (b,c) Kaplan–Meier
survival curves of recipient mice with overexpression of (b) AML1-ETO or (c) AML1-ETO9a (AE9a) in Asxl2 wild-type (WT) or Asxl2-null BM in primary
and secondary transplantation assays (n¼ 10 mice for each genotype and each round of transplantation). (d) Kaplan–Meier survival curves of recipient
mice transplanted with Mx1-cre Aml1-Eto control or Mx1-cre Aml1-Eto Asxl2ﬂ/WT BM with or without NRASG12D overexpression (n¼8 mice for each
genotype). (e,f) Photograph of representative recipient of Mx1-cre Aml1-Eto Asxl2ﬂ/WTmouse at necropsy revealing (e) extramedullary leukemic mass
over heart (red box), hepatosplenomegaly and (f) circulating blasts (scale bars, 25 mm, Wright-Giemsa stain). (g) Flow cytometric analysis of
extramedullary AML from representative Mx1-cre Aml1-Eto Asxl2ﬂ/WTmouse (tissue from red box in e. (h) ATAC-Seq proﬁles (displayed as read
counts per million mapped reads) at the HoxA (left) and Meis1 (right) loci in GFPþ/c-Kitþ cells from two different AE9a/Mx1-cre control (grey) and
AE9a/Mx1-cre Asxl2ﬂ/ﬂ (blue) mice. P values calculated by log-rank test.
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promotes AML1-ETO leukemogenesis by altering enhancer
accessibility at key leukemogenic loci.
Discussion
Mutations in genes encoding Polycomb4,5,26,27,44 and Trithorax45–48
group family members and their associated proteins are amongst the
most common genetic alterations in haematological malignancies.
Mutations in the polycomb-associated protein ASXL1 are present
across the myeloid neoplasms and ubiquitously associated
with adverse clinical outcome in every subtype of myeloid
leukemia7,8,49–51. Consistent with the frequency of genetic
alterations of ASXL1 in patients, deletion or mutation of
Asxl1 in vivo results in myelodysplastic syndrome-like disease in
mice26,27. However, the biological effects of Asxl1 loss or mutation
expression in the haematopoietic system are modest26,27 and this has
led to the hypothesis that the function of ASXL2 may be partially
redundant with that of ASXL1 and able to compensate for
the absence of ASXL1 (ref. 52). At the same time, it has been
proposed that ASXL1 and ASXL2 may even have opposing
biological functions13. We therefore set out to understand the
biological and transcriptomic effects of Asxl2 loss in the
haematopoietic system and to compare them to Asxl1 loss. We
identify here that Asxl2 is required for haematopoiesis in a gene
dosage-dependent manner and has non-overlapping biological
functions with Asxl1. Future efforts to compare the direct binding
targets of ASXL1 versus ASXL2 in normal haematopoietic cells,
the compendium of proteins interacting with ASXL1 versus ASXL2,
and distinct domains between the two proteins will be critical
in further understanding the mechanistic basis for the differing
effects of ASXL1 versus ASXL2 loss.
Consistent with the fact that Asxl2 loss resulted in greater
defects in haematopoiesis than Asxl1 loss, Asxl2 deletion was also
associated with a larger number of differentially expressed genes
in HSPCs than deletion of Asxl1. Interestingly, a substantial
number of genes dysregulated by Asxl2 loss appeared to be direct
targets of RUNX1 and AML1-ETO. Recent genomic analysis has
delineated that mutations in ASXL2 are restricted to AML1-ETO
AML14–16,25. This is in stark contrast to mutations in ASXL1,
which are present throughout myeloid neoplasms and also
enriched in clonal haematopoiesis in normal individuals17–19.
These human genetic data suggest that ASXL2 may promote
leukemogenesis or increased self-renewal only in the setting of
expression of AML1-ETO and not in the setting of normal
HSPCs. Consistent with this, we identiﬁed that ASXL2 loss
promoted leukemogenesis in AML1-ETO-expressing HSPCs but
did not promote the self-renewal of normal haematopoietic stem
cells. Loss of Asxl2 even accelerated leukemogenesis of AE9a, a
splice variant of AML1-ETO whose overexpression alone is
leukemogenic41. Although the shorter latency of AE9a/Asxl2-null
leukemias over AML1-ETO/Asxl2-null leukemias is likely to
reﬂect the known enhanced leukemogenicity of AE9a over
AML1-ETO (ref. 41), future efforts to decipher if there is
a speciﬁc functional collaboration between AE9a and ASXL2 loss
may be enlightening. Similarly it will be interesting to compare
the effects of Asxl1 versus Asxl2 loss in the setting of AML1-ETO
or AE9a expression.
Asx proteins were originally identiﬁed as being required for
assisting Polycomb and Trithorax group proteins in maintaining
homeotic gene expression and silencing53,54. Here, ASXL2 loss
in the context of AML1-ETO AML cells was associated with
loss of repressive H3K27me3 modiﬁcations as well as increased
H3K27ac and H3K4me1 signal at enhancers. Currently the
molecular mechanisms by which ASXL2 loss results in these
changes in chromatin state is not known. Recent work has
suggested that the plant homeoﬁnger domain (PHD) of ASXL2
may bind to and inﬂuence monomethylation at H3K4 (ref. 55),
a mark associated with functional enhancers56–58. This potential
function of the ASXL2 PHD domain may provide a mechanistic
explanation for the observation here of alterations of enhancers
with loss of ASXL2. However, further conﬁrmation of the role of
the ASXL2 PHD domain as well as functional comparison to the
PHD domain of ASXL1 is needed.
As noted earlier, despite being among the common fusions in
AML patients, the AML1-ETO fusion protein by itself is not
sufﬁcient to promote overt leukemia20–24. The fact that loss of
even a single copy of Asxl2 promoted leukemogenesis mediated
by endogenous Aml1-Eto expression strongly supports the
concept that Asxl2 is a haploinsufﬁcient tumour suppressor in
the context of this subtype of AML. Genes dysregulated
by ASXL2 loss largely overlapped with those of RUNX1 and
AML1-ETO and were associated with alterations in a number of
genes previously shown to promote myeloid leukemias.
Moreover, in both human and mouse AML1-ETO-expressing
cells, ASXL2 loss was associated with increased chromatin
accessibility at the HoxA locus, expression of which is well
established as promoting myeloid leukemogenesis59–62. Although
the overlap of ASXL2 dysregulated genes and gene targets of
AML1-ETO and RUNX1 suggest potential physical overlap of
ASXL2, AML1-ETO and RUNX1, no physical interaction
between these 3 proteins were detected here. Future efforts to
map Asxl2 binding sites in the context of normal HSPCs
compared with those of Runx1 may be helpful in further
elucidating the basis for the overlap in gene expression between
Asxl2, RUNX1, and AML1-ETO.
Given the paucity of genetically accurate models for
AML1-ETO AML based on co-occurring genetic lesions, the
models presented in this study may be critical for understanding
AML1-ETO disease pathogenesis further in addition to providing
conditional alleles to deﬁne the role of ASXL2 outside of the
haematopoietic system. Overall, these data highlight Asxl2
as critical for normal haematopoiesis as well as a novel
haploinsufﬁcient tumour suppressor in leukemia.
Methods
Human subjects. RNA extracted from peripheral blood or BM mononuclear
cells from adult t(8;21) AML patients was utilzed for RNA sequencing and
included 7 ASXL1/2 wild-type and 5 ASXL2 mutants from the CBF-2006 trial
(EudraCT #2006 005163-26; ClinicalTrials.gov identiﬁer #NCT00428558). The
study was approved by the ethics committee of Nimes University Hospital and by
the Institutional Review Board of the French Regulatory Agency and conducted in
accordance to the Declaration of Helsinki protocol. Molecular and cytogenetic
analyses were performed as described previously15.
Animals. All animals were housed at Memorial Sloan Kettering Cancer Center
(MSKCC). All animal procedures were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committees at MSKCC.
Generation of Asxl2 and Asxl1/2 conditional knockout mice. The Asxl2
allele was deleted by targeting exon 11. Two LoxP sites ﬂanking exon 11 and
a Frt-ﬂanked neomycin selection cassette were inserted in the upstream intron
(Fig. 1a). Ten micrograms of the targeting vector was linearized by NotI and then
transfected by electroporation of C57Bl/6 (B6) embryonic stem cells (ES). After
selection with G418, surviving clones were expanded for PCR analysis to identify
recombinant ES clones. Positive clones identiﬁed by PCR were conﬁrmed
independently by Southern blotting analysis (Supplementary Fig. 1c). DNA was
digested with Mfe l, and electrophoretically separated on a 0.8% agarose gel. After
transfer to a nylon membrane, the digested DNA was hybridized with a probe
targeted against the 30-external region. DNA from C57Bl/6 (B6) mouse strain was
used as a wild-type control. The Asxl2ﬂ mouse line will be available from The
Jackson Laboratory as JAX#030338.
The generated mice (Asxl2ﬂ/ﬂ) were initially crossed to a germline Flp deleter
(Jackson Laboratory) to eliminate the neomycin cassette, and subsequently to the
IFN-a inducible Mx1-cre (Jackson Laboratory) strain. Asxl2ﬂ/ﬂ, Asxl2ﬂ/WT and
Asxl2WT/WT littermate mice were genotyped by PCR with primers Asxl2-F
(50-GCAGGCTCTCTACAAACTCAGTTC-30) and Asxl2-R (50-CAACATC
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GATATTGCTACTGA TAA AGTGAA-30) using the following parameters: 94 C
for 2min, followed by 35 cycles of 94 C for 30 s, 62 C for 30 s and 72 C for 1min,
and then 72 C for 5min. The wild-type allele was detected as a band at 330 bp,
whereas the ﬂoxed allele was detected as a band of 517 bp. Excision after
cre-mediated recombination was conﬁrmed by western blot and quantitative
PCR with reverse transcription.
Cell culture. SKNO-1 cells were purchased from DSMZ (Braunschweig, Germany)
and cultured in RPMI 1640 with 20% FCS, 1% penicillin-streptomycin, and
10 ngml-1 GM-CSF (BD Biosciences).
Transfection and retrovirus production. cDNAs encoding AML1-ETO9a was
digested with NotI and cloned into the NotI multiple cloning site of the
MSCV-IRES-BEX plasmid (pBEX), upstream of the IRES and blue-excited GFP
motifs24. To produce retrovirus capable of expressing AML1-ETO9a, 293T cells
were cotransfected with a pBEX plasmid and MCV-Ecopac using X-treme GENE 9
(Roche) transfection reagent.
Mouse bone marrow transplantation assays. Freshly dissected femora and tibiae
were isolated fromMx1-cre control, Mx1-cre Asxl1ﬂ/ﬂ,Mx1-cre Asxl2ﬂ/ﬂ,Mx1-cre
Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ mice. BM was ﬂushed with a 3-cc insulin syringe into cold PBS
(without Ca2þ and Mg2þ ) supplemented with 2% bovine serum albumin to
generate single cell suspensions. BM cells were spun at 252 g for 5min by
centrifugation and red blood cells (RBCs) were lysed in ammonium chloride-
potassium bicarbonate lysis (ACK) buffer for 5min on ice. After centrifugation,
cells were resuspended in PBS/2% BSA, ﬁltered through a 40 mM cell strainer. For
competitive transplantation experiments, 0.5 106 total BM cells from Mx1-cre
control, Mx1-cre Asxl1ﬂ/ﬂ, Mx1-cre Asxl2ﬂ/ﬂ, Mx1-cre Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ
CD45.2þ mice were mixed with 0.5 106 wild-type CD45.1þ support BM and
transplanted via tail vein injection into 6-week-old lethally irradiated (2 450cGy)
CD45.1þ recipient mice. To activate the conditional alleles, mice were treated with
3 doses of pIpC (12mg kg 1 day 1; GE Healthcare) via intra-peritoneal injection
4 weeks post transplant. Peripheral blood chimerism was assessed every 4 weeks by
ﬂow cytometry. For noncompetitive transplantation experiments, 1 106 total BM
cells from from Mx1-cre control, Mx1-cre Asxl1ﬂ/ﬂ, Mx1-cre Asxl2ﬂ/ﬂ, Mx1-cre
Asxl1ﬂ/ﬂ Asxl2ﬂ/ﬂ CD45.2þ mice were injected into lethally irradiated
(2 450cGy) CD45.1þ recipient mice. Peripheral blood chimerism was assessed as
described in competitive transplantation experiments. Additionally, for each
bleeding whole blood cell counts were measured on an automated blood analyser.
For AML1-ETO and AML1-ETO9a retroviral primary BMT experiments,
donor cells from Mx1-cre control or Mx1-cre Asxl2ﬂ/ﬂ mice were treated with a
single dose of 5-ﬂuoruracil (150mg kg 1) followed by BM harvest from the
femora, tibiae and hip bones 6 days later. RBCs were removed by ACK lysis buffer,
and nucleated BM cells were transduced with viral supernatants containing
MSCV-AML1-ETO9a-IRES-BEX for 2 days followed by injection of 100,000
pBEXþ cells per recipient mouse via tail vein injection into lethally irradiated
(2 450cGy) CD45.1 recipient mice associated with 500,000 wild-type CD45.1þ
support BM. For secondary transplantation experiments, 6-week-old, sub-lethally
irradiated (450cGy) C57/BL6 recipient mice were injected with 1 106 primary
AML1-ETO9a leukemic cells per recipient.
Methylcellulose colony assays. Megakaryocyte colonies were processed using
STEMCELL Technologies’ protocol for MegaCult-C products for Mouse
CFU-Mk Assays. Brieﬂy, LSK cells were sorted by ﬂow cytometry and were
cultured for 10 days in a double chamber culture slide (5,000 cells/chamber) with
serum-free medium containing cytokines (rhThrombopoietin 50 ngml 1, rhIL-6
20 ngml 1, rmIL-3 10 nml 1). After dehydration and ﬁxation the cells were
stained for Megakaryocytes Acetylcholinesterase activity. CFU-Mk that were
acetylcholinesterase positive and contained at least 3 megakaryocytes were counted.
Antibodies. Cell populations were analysed using a FACSFortessa (Becton Dick-
inson) and sorted with a FACSAria II instrument (Becton Dickinson). All FACS
antibodies were purchased from BD Pharmingen, BioLegend or eBioscience. We used
the following antibodies: c-Kit (2B8, Cat# 105808, 1:100), Sca-1 (D7, Cat# 108114,
1:100), B220 (RA3-6B2, Cat# 103222, 1:200), Mac-1/CD11b (M1/70, Cat# 101206,
1:200), Gr-1 (RB6-8C5, Cat# 108412, 1:200), NK1.1 (PK136, Cat# 108724, 1:100),
Ter119 (TER-119, Cat# 116223, 1:100), IL-7R A7R34, Cat# 135014, 1:100), CD3
(17A2, Cat# 100222, 1:100), CD4 (RM4-5, Cat# 100526, 1:100), CD8 (53-6.7, Cat#
100712, 1:100), CD16/32 (93, Cat# 56-0161-82, 1:100), CD34 (RAM34, Cat# 11-
0341-85, 1:100), CD41 (MWReg30, Cat# 133916, 1:100), CD45.1 (A20, Cat# 110738,
1:100), CD45.2 (104, Cat# 109822, 1:100), CD48 (HM48-1, Cat# 103422, 1:100),
CD71 (RI7217.1.4, Cat# 12-1501-82,1:100), and CD150 (mShad150, Cat# 12-1502-
82,1:100).
The following antibodies were used for Western Blot analysis: anti-ASXL2
(Bethyl laboratories A302-037A, 1:2,000), anti-ASXL1 (Santa-Cruz sc-85283,
1:200), anti-beta-Actin (Sigma-Aldrich A5441, 1:1,000) and anti-Tubulin
(Sigma-Aldrich T6199, 1:1000).
Antibodies used for ChIP include anti-H3K4me3 (Cell Signaling 9751S, 1:50),
anti-H3K27ac (Abcam ab4729, 2 mg for 25 mg of chromatin) and anti-H3K4me1
(Abcam ab8895, 2 mg for 25mg of chromatin), anti-H3K27me3 (Millipore 07–449,
2 mg for 25 mg of chromatin), anti-ASXL1 (Santa Cruz sc-98302, 1:50) and anti-
ASXL2 (Bethyl A302–037A, 2 mg for 25mg of chromatin).
Histone extraction. Histones were extracted using the Active Motif Histone
Extraction Minikit (Active Motif 40026).
ChIP-Seq and motif analysis. For ChIP-seq in murine cells 10 million BM c-Kitþ
cells (isolated with anti–mouse CD117 microbeads (Miltenyi Biotec)) were used.
For ChIP in SKNO-1 cells, 10 millions of GFPþ cell were used. Brieﬂy, cells were
ﬁxed in a 1% methanol-free formaldehyde solution and then resuspended in
sodium dodecyl sulfate (SDS) lysis buffer. Lysates were sonicated in an E220
focused-ultrasonicator (Covaris) to a desired fragment size distribution of 100–500
base pairs. IP reactions were performed with the indicated antibodies, each on
approximately 500,000 cells63. ChIP assays were processed on an SX-8G IP-STAR
Compact Automated System (Diagenode) using a direct ChIP protocol as described
elsewhere64. Eluted chromatin fragments were then de-crosslinked and the DNA
fragments puriﬁed using Agencourt AMPure XP beads (Beckman Coulter).
Barcoded libraries were prepared from the ChIP-enriched and input DNA using
a NEBNext ChIP-seq Library Prep Master Mix Set for Illumina (New England
BioLabs) and TruSeq Adaptors (Illumina) according to the manufacturer’s
instructions on an SX-8G IP-STAR Compact Automated System (Diagenode).
Phusion High-Fidelity DNA Polymerase (New England BioLabs) and TruSeq
PCR Primers (Illumina) were used to amplify the libraries, which were then
puriﬁed to remove adaptor dimers using AMPure XP beads and multiplexed
on the HiSeq 2000 (Illumina). Previosuly published anti-RUNX1 and AML1-ETO
ChIP-seq were downloaded from the NCBI Gene Expression Omnibus
(GEO;http://www.ncbi.nlm.nih.gov/geo/) under accession no. GSE23730 (ref. 30).
Raw ChIP-seq data were analysed using Basepair software
(http://www.basepairtech.com/) with pipelines including the following steps: the
raw fastq data were trimmed using trim_galore to remove low-quality ends from
reads (qualityo15) and adapter sequences. The trimmed data was aligned using
Bowtie2 (ref. 65) to UCSC genome assembly hg19 (for human samples) or mm9
(for mouse samples). Duplicate reads were removed using Picard and bigwig ﬁles
were created for visualization. Peaks were identiﬁed with Macs1.4 (ref. 66) and
transcription factor binding motifs were detected with Homer. Peaks overlapping
with Satellite repeat regions were discarded and remaining ﬁltered peaks were
annotated using custom scripts based on UCSC refFlat data67, where peaks
between  2500 bp to 2500 bp of a transcription start site were marked as
Promoter, the overlapping gene body were marked as Genebody and the rest were
marked as Intergenic. For intergenic peaks, a gene was considered a target if it was
within 1Mb of the peak. All ChIP-seq reads were normalized and displayed as read
counts per million mapped reads.
ATAC-seq. ATAC-seq was performed as previously described68. For each sample,
nuclear extracts were prepared from 50,000 cells, and incubated with 2.5 ml of
transposase (Illumina) in a 50 ml reaction for 30min at 37 C. After puriﬁcation of
transposase-fragmented DNA, the library was ampliﬁed by PCR and subjected to
high-throughput sequencing using the HiSeq 2000 platform (Illumina). ATAC-seq
reads were normalized and displayed as read counts per million mapped reads.
mRNA, sequencing. RNA-Seq was conducted with three biological replicates from
each group. Genetic phenotyping experiments were replicated three times inde-
pendently. RNA was extracted from sorted mouse cell populations using Qiagen
RNeasy columns. poly(A)-selected, unstranded Illumina libraries were prepared
with a modiﬁed TruSeq protocol. 0.5X AMPure XP beads were added to the sample
library to select for fragments o400 bp, followed by 1X beads to select for frag-
ments 4100 bp. These fragments were then ampliﬁed with PCR (15 cycles) and
separated by gel electrophoresis (2% agarose). 300 bp DNA fragments were isolated
and sequenced on the Illumina HiSeq 2000 (B100M 101 bp reads per sample).
Differential expression tests were performed using the Cuffdiff module of Cufﬂinks
with RefSeq genes provided as an annotation (N, andM options engaged).
We considered genes that had a Po0.05 to be signiﬁcantly different between
genotypes.
Statistical analyses. Data were analysed using GraphPad Prism 7 software.
A 2-tailed Student’s T test was performed in 2-group comparisons. When
comparing multiple groups, one-way analysis of variance followed by Tukey’s
post-hoc test was performed. *Po0.05; **Po0.01; **Po0.001. A log-ranked
(Mantel–Cox) test was used to calculate statistical signiﬁcance in Kaplan–Meier
survival studies.
Histological analyses. Mice were sacriﬁced and autopsied, and then dissected
tissue samples were ﬁxed for 24 h in 4% paraformaldehyde, dehydrated, and
embedded in parafﬁn. Parafﬁn blocks were sectioned at 4 mm and stained with
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haematoxylin and eosin (H&E). Images were acquired using an Axio Observer A1
microscope (Carl Zeiss).
Analysis of protein stability. HEK293T cells were transfected with full-
length wild-type ASXL2 cDNA or ASXL2 cDNAs bearing ASXL2 mutations
(p.E1287X, p.T740NfsX16)) followed by treatment with DMSO or cycloheximide
(100 ugml 1). After 12 h exposure cells were harvested and results were analysed
by western blotting using ASXL2 antibody. The Quantiﬁcation of the 3estern bands
was done using ImageJ Software.
Data availability. All ChIP-, ATAC-, and RNA-seq data from this study are
deposited in the Gene Expression Omnibus (GEO) under accession number
GSE84365. All other remaining data are available within the Article and
Supplementary Files, or available from the authors upon request.
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